Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01097746
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:55.975847+00:00
Published At
2022-06-10T00:00:00+00:00
Record Updated At
2022-10-28
Results Posted At
2022-06-10
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Fallopian Tube Carcinoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "FIGO Stage III Ovarian Cancer", "FIGO Stage IIIA Ovarian Cancer", "FIGO Stage IIIA1 Ovarian Cancer", "FIGO Stage IIIA1(i) Ovarian Cancer", "FIGO Stage IIIA1(ii) Ovarian Cancer", "FIGO Stage IIIA2 Ovarian Cancer", "FIGO Stage IIIB Ovarian Cancer", "FIGO Stage IIIC Ovarian Cancer", "FIGO Stage IVA Ovarian Cancer", "FIGO Stage IVB Ovarian Cancer", "Malignant Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Carcinoma", "Primary Peritoneal Serous Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-10-28"
protocolSection.identificationModule.nctId
"NCT01097746"
protocolSection.identificationModule.officialTitle
"A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2022-06-10"

Study condition terms

  • Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • FIGO Stage III Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • FIGO Stage IIIA Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • FIGO Stage IIIA1 Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • FIGO Stage IIIA1(i) Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • FIGO Stage IIIA1(ii) Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • FIGO Stage IIIA2 Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • FIGO Stage IIIB Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • FIGO Stage IIIC Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • FIGO Stage IVA Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • FIGO Stage IVB Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Malignant Ovarian Brenner Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Seromucinous Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.